LENZ Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
LENZ$4.10-4.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net loss | $(37,117) | $(46,276) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 33 | 11 |
| Accretion of discounts on marketable securities | (2,593) | (546) |
| Change in fair value of preferred stock warrants | 1,047 | 146 |
| Share-based compensation expense | 4,735 | 825 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (684) | 485 |
| Accounts payable | (5,599) | (232) |
| Accrued liabilities | (8,758) | 6,167 |
| Other assets | (1,377) | 10 |
| Net cash used in operating activities | (50,313) | (39,410) |
| Cash flows from investing activities | ||
| Purchases of marketable securities | (195,297) | (46,264) |
| Proceeds from maturities of marketable securities | 53,000 | 1,500 |
| Purchases of property and equipment | (319) | (30) |
| Net cash used in investing activities | (142,616) | (44,794) |
| Cash flows from financing activities | ||
| Proceeds from issuance of Series B convertible preferred stock, net of issuance costs | — | 82,976 |
| Deferred offering costs | — | (568) |
| Proceeds from issuance of common stock, net of issuance costs | 79,598 | — |
| Cash, cash equivalents, and restricted cash acquired in connection with the Merger | 117,824 | — |
| Merger transaction costs | (2,373) | — |
| Proceeds from exercises of stock options | 3,900 | 203 |
| Net cash provided by financing activities | 198,949 | 82,611 |
| Net increase in cash, cash equivalents, and restricted cash | 6,020 | (1,593) |
| Cash and cash equivalents, beginning of the period | 35,140 | 44,441 |
| Cash, cash equivalents, and restricted cash, end of the period | $41,160 | $42,848 |
| Supplemental cash flow information | ||
| Conversion of Series A, A-1, and B convertible preferred stock to common stock | $137,490 | $— |
| Conversion of Class B convertible common stock to common stock | $5,900 | $— |
| Reclassification of warrant liability to equity | $1,918 | $— |
| Prepaid expenses and other current assets assumed in the Merger | $1,313 | $— |
| Accounts payable and accrued liabilities assumed in the Merger | $2,950 | $— |
| Common stock issuance costs included in accounts payable and accrued expenses | $81 | $— |
| Right-of-use assets assumed in the Merger in exchange for operating lease liabilities | $146 | $— |
| Right-of-use assets obtained in exchange for operating lease liabilities | $1,205 | $190 |
| Property and equipment included in accrued expenses | $32 | $— |
| Deferred offering costs included in accounts payable and accrued expenses | $— | $1,298 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.